Progress on medication-related osteonecrosis of the jaw.

Author: Qi-Zhang WANG ¹ ; Ji-Yuan LIU ¹ ; Jian PAN ¹
Author Information

1. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Publication Type:Journal Article
Keywords: bevacizumab; bisphosphonates; denosumab; osteonecrosis
MeSH: Angiogenesis Inhibitors; therapeutic use; Bisphosphonate-Associated Osteonecrosis of the Jaw; drug therapy; Bone Density Conservation Agents; adverse effects; Denosumab; therapeutic use; Diphosphonates; Humans
From: West China Journal of Stomatology 2018;36(5):568-572
CountryChina
Language:Chinese
Abstract: Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication of bisphosphonates (BPs) or other targeted agent therapies. MRONJ appears as exposed bone, pus, and swelling in the oral and maxillofacial regions. However, neither surgery nor conservative therapy can eliminate symptoms thoroughly. In addition to BPs, several antiresorptive and antiangiogenic agents, such as denosumab and bevacizumab, as well as targeted agents, such as sunitinib and temsirolimus, can cause osteonecrosis of the jaw according to the literature. This review aims to summarize the research progress on these new drugs.